Background: Patients with chronic obstructive pulmonary disease (COPD) and suboptimal
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …

Background: A peak inspiratory flow rate (PIFR) of< 60 L/min against the internal resistance
(resist) of a dry powder inhaler (DPI) may limit the ability of a patient with chronic obstructive …

Background The chronic and progressive nature of chronic obstructive pulmonary disease
(COPD) requires self-administration of inhaled medication. Dry powder inhalers (DPIs) are …

Background The influence of peak inspiratory flow (PIF) on dose delivery from dry powder
inhalers (DPIs) and association with treatment efficacy in patients with chronic obstructive …

Background Prior replicate 12-week phase 3 trials demonstrated that once-daily doses of
revefenacin inhalation solution at 88 μg and 175 μg produced significant bronchodilation …

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the
United States with a significant economic burden related to hospital admissions for …

Background Three 52-week studies in COPD have assessed the efficacy and safety of
single-inhaler extrafine formulation triple therapy combining beclomethasone dipropionate …

Objectives: Determine the prevalence of suboptimal peak inspiratory flow rate (PIFR) and
associated patient characteristics and compare PIFR measurements obtained with …

Current guidelines recommend inhalation therapy as the preferred route of drug
administration for treating patients with chronic obstructive pulmonary disease (COPD) …

Abstract Background Revefenacin (TD-4208) is a potent, lung-selective, long-acting
muscarinic antagonist currently in development as a once-daily nebulized therapy for …